Supplementary Data from Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201)

This includes Supplementary Table 1 with all adverse events by arm. Supplementary Figure 1 shows best overall response in patients with restaging imaging. Supplementary Figure 2 shows all somatic mutations, including those identified in an exploratory fashion.